ストックスクリーナーアプリを入手
40.08
4.36%
1.475
前日終値:
$38.60
開ける：
$39.31
24時間の取引高:
604.27K
Relative Volume:
1.01
時価総額：
$1.49B
収益：
$154.15M
当期純損益:
$-33.58M
株価収益率:
-41.75
EPS:
-0.96
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
-24.61%
1か月 パフォーマンス:
-14.64%
6か月 パフォーマンス:
+11.30%
1年 パフォーマンス:
+54.31%
1日の値動き範囲:
$37.52
$40.38
1週間の範囲:
$37.52
$54.49
52週間の値動き範囲:
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
40.13 | 1.43B | 154.15M | -33.58M | -20.74M | -0.96 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.14 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.71 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.52 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.58 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
496.12 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 開始されました | BTIG Research | Buy |
| 2025-06-10 | 開始されました | William Blair | Outperform |
| 2025-02-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-04 | 繰り返されました | B. Riley Securities | Buy |
| 2024-04-11 | 開始されました | Craig Hallum | Buy |
| 2022-09-08 | 再開されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2021-09-24 | 開始されました | Aegis Capital | Buy |
| 2021-07-02 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Harrow Inc (HROW) 最新ニュース
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday.com
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Nasdaq
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
Harrow (HROW) Sets Ambitious Financial Targets for FY26 - GuruFocus
Harrow Reports Q4 Earnings - National Today
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - Bitget
Harrow Health Posts Record 2025 Results, Sets 2026 Outlook - TipRanks
Harrow: Q4 Earnings Snapshot - Citizen Tribune
Harrow Health Stock Slides After 2026 Outlook Shock - TipRanks
Harrow Inc. (HROW) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Harrow : Q4-2025 Letter to Stockholders - marketscreener.com
Harrow Earnings Review: Q4 Summary - Benzinga
HROW: 2025 revenue surged 36% to $272.3M, net loss narrowed, and branded sales led growth - TradingView
Harrow 10-K: $272.3M Revenue, $(0.14) EPS on improved net loss - TradingView
[10-K] HARROW, INC. Files Annual Report | HROW SEC FilingForm 10-K - Stock Titan
Earnings Flash (HROW) Harrow Posts Q4 EPS $0.17, vs. FactSet Est of $0.37 - marketscreener.com
Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook - Stock Titan
Why Is Eye-Disease-Focused Harrow Stock Falling Today? - Bitget
Earnings Flash (HROW) Harrow, Inc. Reports Q4 Revenue $89.1M, vs. FactSet Est of $90.0M - marketscreener.com
All eyes on Harrow Health earnings amid VEVYE coverage win - Investing.com
Harrow, Inc. $HROW Shares Sold by Royce & Associates LP - MarketBeat
88,855 Shares in Harrow, Inc. $HROW Bought by Lumbard & Kellner LLC - MarketBeat
Harrow: Q4 Financial Overview - Bitget
Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance
HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Harrow Health (HROW) Set to Announce Q4 Earnings - GuruFocus
A Preview Of Harrow's Earnings - Benzinga
Harrow’s PharmaPack Aims To Reshape Cataract Surgery Prescribing And Access - simplywall.st
Harrow Bets On AI And PharmaPack To Reshape Ophthalmic Distribution - Yahoo Finance
Is It Too Late To Look At Harrow Health (HROW) After Its 1-Year 90% Surge? - simplywall.st
Harrow, Inc. (HROW) Investor Outlook: A Potential 37% Upside in the Eyecare Pharmaceuticals Sector - DirectorsTalk Interviews
Harrow (HROW) Is Up 8.1% After Launching PharmaPack Cash-Pay Ophthalmic Kits For Cataract Surgery - simplywall.st
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
FOMO Trade: Does Harrow Inc have strong EBITDA marginsMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Will Harrow Inc. stock attract more institutional investorsMarket Growth Report & Expert Verified Movement Alerts - mfd.ru
Harrow to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 - The Manila Times
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - markets.businessinsider.com
Harrow, Inc. Announces Cash-Pay Direct-To-Prescriber Pharmapack?? Kits - marketscreener.com
Harrow Inc (HROW) 財務データ
収益
当期純利益
現金流量
EPS
Harrow Inc (HROW) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
1.71%
0.34%
大文字化:
|
ボリューム (24 時間):